Lifecore Biomedical (LDE) Ratios
Lifecore Biomedical Ratios
DE:LDE's free cash flow for Q4 2026 was $-986.28K. For the 2026 fiscal year, DE:LDE's free cash flow was decreased by $-1.52M and operating cash flow was $535.72K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | May 25 | May 24 | Aug 23 | May 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.49 | 2.84 | 2.08 | 2.39 | 0.66 |
| Quick Ratio | 2.26 | 1.77 | 1.06 | 1.35 | 0.46 |
| Cash Ratio | 0.74 | 0.27 | 0.22 | 0.49 | 0.01 |
| Solvency Ratio | -0.09 | -0.13 | 0.08 | -0.34 | -0.53 |
| Operating Cash Flow Ratio | 0.53 | -0.01 | 0.01 | -0.44 | -0.13 |
| Short-Term Operating Cash Flow Coverage | 16.26 | -0.06 | 0.27 | -30.07 | -0.16 |
| Net Current Asset Value | $ -164.09M | $ -152.33M | $ -161.61M | $ -163.90M | $ -70.21M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.61 | 0.55 | 0.53 | 0.44 | 0.90 |
| Debt-to-Equity Ratio | -10.04 | 97.92 | 11.81 | -26.63 | 2.82 |
| Debt-to-Capital Ratio | 1.11 | 0.99 | 0.92 | 1.04 | 0.74 |
| Long-Term Debt-to-Capital Ratio | 1.12 | 0.99 | 0.92 | 1.04 | 0.53 |
| Financial Leverage Ratio | -16.35 | 179.15 | 22.44 | -59.94 | 3.13 |
| Debt Service Coverage Ratio | -5.32 | -0.35 | 1.86 | -1.84 | 0.12 |
| Interest Coverage Ratio | 0.57 | -0.79 | -0.49 | -1.23 | -0.76 |
| Debt to Market Cap | 0.50 | 0.56 | 0.73 | 0.43 | 0.81 |
| Interest Debt Per Share | 4.22 | 4.38 | 4.98 | 4.35 | 8.94 |
| Net Debt to EBITDA | 15.18 | -13.91 | 3.51 | -2.82 | 19.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 31.37% | 31.27% | 32.63% | 27.10% | 35.11% |
| EBIT Margin | -0.97% | -13.07% | 21.52% | -44.88% | -4.69% |
| EBITDA Margin | 6.37% | -6.84% | 27.76% | -32.12% | 11.54% |
| Operating Profit Margin | -0.97% | -13.38% | -6.90% | -21.11% | -10.60% |
| Pretax Profit Margin | -23.34% | -30.01% | 7.42% | -61.90% | -18.59% |
| Net Profit Margin | -23.78% | -30.04% | 9.37% | -96.41% | -104.89% |
| Continuous Operations Profit Margin | -23.78% | -30.04% | 7.28% | -62.20% | -13.91% |
| Net Income Per EBT | 101.91% | 100.11% | 126.27% | 155.74% | 564.19% |
| EBT Per EBIT | 2404.36% | 224.26% | -107.58% | 293.30% | 175.45% |
| Return on Assets (ROA) | -13.26% | -16.18% | 4.73% | -39.27% | -42.49% |
| Return on Equity (ROE) | 216.80% | -2897.98% | 106.17% | 2353.74% | -132.90% |
| Return on Capital Employed (ROCE) | -0.60% | -8.24% | -4.11% | -10.17% | -12.02% |
| Return on Invested Capital (ROIC) | -0.60% | -8.10% | -3.94% | -10.09% | -3.67% |
| Return on Tangible Assets | -14.10% | -17.50% | 5.09% | -42.28% | -45.48% |
| Earnings Yield | -11.32% | -16.55% | 7.01% | -41.86% | -40.13% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.83 | 2.95 | 4.12 | 3.56 | 2.90 |
| Payables Turnover | 15.22 | 10.77 | 5.29 | 3.41 | 5.57 |
| Inventory Turnover | 3.06 | 2.74 | 2.16 | 1.84 | 2.01 |
| Fixed Asset Turnover | 1.02 | 1.00 | 0.86 | 0.74 | 0.90 |
| Asset Turnover | 0.56 | 0.54 | 0.51 | 0.41 | 0.41 |
| Working Capital Turnover Ratio | 2.27 | 2.64 | 2.65 | -38.77 | -16.51 |
| Cash Conversion Cycle | 190.83 | 222.88 | 188.53 | 193.46 | 242.19 |
| Days of Sales Outstanding | 95.34 | 123.68 | 88.65 | 102.58 | 125.68 |
| Days of Inventory Outstanding | 119.48 | 133.07 | 168.87 | 198.01 | 181.98 |
| Days of Payables Outstanding | 23.99 | 33.88 | 68.99 | 107.13 | 65.47 |
| Operating Cycle | 214.82 | 256.76 | 257.53 | 300.59 | 307.67 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.38 | -0.01 | 0.01 | -0.58 | -0.77 |
| Free Cash Flow Per Share | 0.19 | -0.39 | -0.60 | -1.30 | -1.78 |
| Dividend Paid and CapEx Coverage Ratio | 1.98 | -0.02 | 0.01 | -0.81 | -0.75 |
| Capital Expenditure Coverage Ratio | 1.98 | -0.02 | 0.01 | -0.81 | -0.75 |
| Operating Cash Flow Coverage Ratio | 0.09 | -0.00 | 0.00 | -0.15 | -0.09 |
| Operating Cash Flow to Sales Ratio | 0.10 | -0.00 | 0.00 | -0.17 | -0.20 |
| Free Cash Flow Yield | 2.29% | -5.82% | -10.59% | -16.36% | -18.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.89 | -5.29 | 14.26 | -2.39 | -2.49 |
| Price-to-Sales (P/S) Ratio | 2.10 | 1.82 | 1.34 | 2.30 | 2.61 |
| Price-to-Book (P/B) Ratio | -19.16 | 175.14 | 15.14 | -56.23 | 3.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 43.67 | -17.18 | -9.44 | -6.11 | -5.54 |
| Price-to-Operating Cash Flow Ratio | 21.65 | -1135.84 | 666.40 | -13.64 | -12.87 |
| Price-to-Earnings Growth (PEG) Ratio | 0.32 | 0.01 | -0.13 | 0.15 | -0.01 |
| Enterprise Value Multiple | 48.19 | -40.46 | 8.32 | -9.99 | 41.86 |
| Enterprise Value | 397.22M | 356.54M | 296.38M | 331.40M | 537.62M |
| EV to EBITDA | 48.19 | -40.46 | 8.32 | -9.99 | 41.86 |
| EV to Sales | 3.07 | 2.77 | 2.31 | 3.21 | 4.83 |
| EV to Free Cash Flow | 63.76 | -26.18 | -16.34 | -8.51 | -10.23 |
| EV to Operating Cash Flow | 31.61 | -1730.78 | 1153.22 | -19.00 | -23.80 |
| Tangible Book Value Per Share | -0.84 | -0.48 | -0.22 | -0.74 | 2.37 |
| Shareholders’ Equity Per Share | -0.43 | 0.04 | 0.37 | -0.14 | 2.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | -0.00 | 0.02 | -0.00 | 0.25 |
| Revenue Per Share | 3.89 | 3.70 | 4.21 | 3.45 | 3.78 |
| Net Income Per Share | -0.93 | -1.11 | 0.39 | -3.32 | -3.96 |
| Tax Burden | 1.02 | 1.00 | 1.26 | 1.56 | 5.64 |
| Interest Burden | 24.04 | 2.30 | 0.34 | 1.38 | 3.97 |
| Research & Development to Revenue | 0.07 | 0.06 | 0.07 | 0.08 | 0.07 |
| SG&A to Revenue | 0.26 | 0.34 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.05 | 0.08 | 0.05 | 0.03 | 0.02 |
| Income Quality | -0.40 | 0.01 | 0.02 | 0.18 | 0.19 |
Currency in USD
